Date: April 23, 2024
Time: 4PM CEST, 7AM PST, 10AM EST
Preimplantation genetic testing (PGT) has become commonplace in research during in vitro fertilisation (IVF) procedures. Various PGT methods are utilised to assess blastocysts suitability for implantation. In this roundtable, we focus on PGT for monogenic disorders (PGT-M) specifically within the public sector, analysing the presence of genetic mutations in single gene linked disorders. Join us and our panel of experts for a comprehensive overview, current breakthroughs, and the exciting prospects of PGT-M technology within the public sector.
Learning objectives:
- Discover the past, present and future of PGT-M
- Listen to experts sharing their experiences with PGT-M in the public sector including insights into managing challenging cases
- Gain a comprehensive understanding of how PGT-M testing is performed in public hospitals
- Understand the market trends and dynamics of PGT-M testing in the EMEA region
- Have an opportunity to engage with our speakers in the Q&A session
Webinars will be available for unlimited on-demand viewing after live event.
Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or application of Thermo Fisher Scientific products presented by third parties in this presentation. Information and materials presented or provided by third parties are provided as-is and without warranty of any kind from Thermo Fisher Scientific, including regarding intellectual property rights and reported results. Parties presenting images, text and material represent they have the rights to do so.